" class="no-js "lang="en-US"> Woebot Health Names Matt Borowiecki Chief Financial Officer
Friday, April 12, 2024

Woebot Health Names Matt Borowiecki Chief Financial Officer

Woebot Health, a mental health ally for people and businesses, today announced that it has appointed Matt Borowiecki as its Chief Financial Officer. A member of the senior management team, Borowiecki will lead the company’s financial operations and strategy, including management and financial reporting, budgeting and long-term financial planning, and will also manage its capital structure. He reports to Chief Executive Officer Michael Evers.

Borowiecki has more than 20 years of global experience in finance, strategy and corporate development across healthcare, insurance and financial services, and has managed acquisitions, divestitures, joint ventures and debt and equity financings totaling more than $60 billion of value. Before joining Woebot Health, Borowiecki was the Chief Financial Officer at Biofourmis, a technology-enabled care delivery and digital therapeutics company. In that position, he led Biofourmis’ financial operations as it scaled revenue, customers and employees and surpassed unicorn status. Before that, Borowiecki was the Head of Capital Transactions and Structuring at MassMutual Financial Group. His healthcare industry experience dates to 2011 when he joined Aetna as its Director of Corporate Development and Enterprise Strategic Planning. Previously Borowiecki held positions of increasing responsibility at leading investment banks Morgan Stanley, Lehman Brothers and UBS.

“Matt’s deep understanding of the healthcare industry and investment acumen will be instrumental as we mature our operations and move to the next level of our company’s growth,” said Evers. “His strategic experience is complemented by a deep compassion and commitment to helping people access the mental health care they need. We’re delighted he’s joined at this very pivotal moment.”

“The last few years have placed a spotlight on mental health, while the last few months have seen incredible advances in technologies that can play a role in changing the way we deliver care,” said Matt Borowiecki. “We have the opportunity to really make a difference in patients’ lives, and that’s extremely motivating.”

Borowiecki holds a Master of Business Administration degree from the Tuck School of Business at Dartmouth and a Bachelor of Arts degree in Economics from Kenyon College. He is an avid traveler who has visited 47 countries and dependencies and 44 U.S. states.

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more